News: Synta Pharmaceuticals Corp (SNTA.OQ)
SNTA.OQ on NASDAQ Stock Exchange Global Market
6.09USD
1 Aug 2013
6.09USD
1 Aug 2013
Price Change (% chg)
$-0.62 (-9.24%)
$-0.62 (-9.24%)
Prev Close
$6.71
$6.71
Open
$6.64
$6.64
Day's High
$6.90
$6.90
Day's Low
$6.04
$6.04
Volume
617,019
617,019
Avg. Vol
463,669
463,669
52-wk High
$11.77
$11.77
52-wk Low
$3.77
$3.77
Select another date:
Mon, Jul 29 2013
Synta Pharma shares soar after co says to expand breast cancer study
- Synta Pharmaceuticals Corp shares soared as much as 47 percent in heavy trading after the company said preliminary results from a mid-stage study of its drug ganetespib in breast cancer patients supported an expansion of the study.
Select another date:
- 3 Small Biotech Firms In The Spotlight
- Synta's Anti-Cancer Therapy Data Extremely Positive And More Upside Is Likely
- Synta Suffers From Premature Stock Promotion Syndrome
- 3 Horrendous Health-Care Stocks This Week
- Strong Data Suggests Synta Pharmaceuticals Has A 40% Upside From Here And Probably More
- 4 Biotech Stocks Under $10 Making Big Moves
Press Releases
- Synta Pharmaceuticals Announces $60 Million Registered Direct Common Stock Offering
- Synta Pharmaceuticals Announces Proposed Registered Direct Offering of Common Stock
- Synta to Present at the Deutsche Bank 2012 dbAccess BioFEST
- Interim Results of the Phase 2b/3 GALAXY Trial to be Presented at the Fifth Asia Pacific Lung Cancer Conference
- Synta to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
- Interim Results of the Phase 2b GALAXY Trial to be Presented at the Chemotherapy Foundation Symposium
- Synta Provides Clinical Update and Reports Third Quarter 2012 Financial Results
- Synta to Host Third Quarter 2012 Conference Call on November 6, 2012
- Updated Results from Phase 2b/3 GALAXY Trial Show Promising Improvement in Survival from the Addition of Ganetespib to Docetaxel in Second-Line Non-Small Cell Lung Cancer
- Updated Results from Phase 2b/3 GALAXY Trial Show Promising Improvement in Survival from the Addition of Ganetespib to Docetaxel in Second-Line Non-Small Cell Lung Cancer

